CLEVELAND, July 9, 2019 /PRNewswire/
-- Vanderbilt-Ingram Cancer Center and GenomOncology LLC
announce the launch of the newly redesigned and improved My Cancer
Genome website. The new site showcases the breadth and depth of
curated content from My Cancer Genome.
Powered by GenomOncology's Precision Oncology Platform, the site
offers clinicians, researchers and patients access to a wealth of
information about the latest developments in precision cancer
medicine. Using powerful search and filtering technology, users can
explore clinical trials, biomarkers, diseases, drugs or pathways.
My Cancer Genome ties together the body of knowledge on precision
cancer medicine.
The improvements with www.mycancergenome.org include:
- New Search and Navigation - search directly for
relevant content or drill down to more detailed information.
- Expanded Content - Detail pages combine visual
representations with curated content, GENIE1 data, NCI
definitions, and more.
- Enhanced Clinical Trial Searching - Robust
faceting allows targeted clinical trial searches based on disease
and biomarker eligibility criteria, phase, and recruiting
status.
- Therapies in Context - Therapies are displayed
within the context of the related biomarker, disease, or drug
page.
"Ever since the release of the first version of My Cancer
Genome, we have been envisioning an updated version that enables us
to scale and expand our content. This release realizes the vision
of that long-term goal and enhances the website's features to drive
precision cancer medicine treatment."
- Mia Levy, M.D., Ph.D. Levy co-founded My
Cancer Genome, the nation's first web-based precision cancer
knowledge resource, in 2011.
"Our goal in creating this new website was to retain the focus
on what clinicians, researchers, and patients need and want out of
a precision oncology website, while at the same time greatly
expanding the content. We are also very excited to present our much
improved clinical trial search tool," said Christine Micheel, Ph.D., co-lead of My Cancer
Genome.
"The new My Cancer Genome site is designed for flexibility and
adaptability, providing both curated and calculated content to
physicians, researchers and patients. This tool will allow those
practicing in oncology or affected by cancer the ability to find
and apply real-time content. We are excited to partner with
Vanderbilt and the My Cancer Genome
team to bring this new capability to market."
- Brad Wertz, CEO of GenomOncology
To develop the new website, the My Cancer Genome team worked
with development partner and content licensee GenomOncology.
Additional features of My Cancer Genome will continue to be rolled
out in a series of releases as the next phase of the website is
completed. For more information on My Cancer Genome, visit
www.mycancergenome.org.
About My Cancer Genome
Vanderbilt-Ingram Cancer Center launched My Cancer Genome in
January 2011 to help physicians and
researchers track the latest developments in precision cancer
medicine and connect with clinical research trials.
About GenomOncology
GenomOncology has the leading precision oncology platform powered
by its proprietary Knowledge Management System (KMS) which enables
clinical decision support, virtual molecular tumor boards, clinical
trial matching, and advanced analytics. The solutions power
clinical decision-making at innovative cancer centers and
laboratories worldwide. More information can be found on the
company's website at www.genomoncology.com.
1 The AACR Project GENIE Consortium. AACR
Project GENIE: Powering Precision Medicine Through An International
Consortium, Cancer Discov. 2017 Aug;7(8):818-831. Dataset
Version 5.
For more information about GenomOncology:
Teresa Fletcher
Vice President, Business Development
Tel: 646-327-3932
Email: teresa@genomoncology.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/improved-website-for-my-cancer-genome-launched-300879277.html
SOURCE GenomOncology